{
    "clinical_study": {
        "@rank": "58918", 
        "brief_summary": {
            "textblock": "RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing\n      so they stop growing or die.\n\n      PURPOSE: Phase II trial to study the effectiveness of aminocamptothecin in treating patients\n      with advanced cutaneous T-cell lymphoma."
        }, 
        "brief_title": "Aminocamptothecin in Treating Patients With T-cell Lymphoma", 
        "completion_date": {
            "#text": "April 2000", 
            "@type": "Actual"
        }, 
        "condition": "Lymphoma", 
        "condition_browse": {
            "mesh_term": [
                "Lymphoma", 
                "Lymphoma, T-Cell", 
                "Lymphoma, T-Cell, Cutaneous"
            ]
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES: I. Assess the antitumor activity of aminocamptothecin (9-AC) administered by\n      72-hour infusion in patients with advanced cutaneous T-cell lymphoma. II. Assess the toxic\n      effects of 9-AC administered on this schedule.\n\n      OUTLINE: Single-Agent Chemotherapy. Aminocamptothecin, 9-AC, NSC-603071.\n\n      PROJECTED ACCRUAL: A total of 30 patients will be accrued; if no more than 1 response is\n      seen in the first 15 patients, the study will close. Probable duration of study is 18\n      months."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS: Histologically confirmed, advanced stages IIB/III/IV cutaneous\n        T-cell lymphoma Measurable or evaluable disease required Measurable disease includes: Skin\n        disease evaluated by clinical assessment grid method Lesion measurable on imaging (i.e.,\n        CT measurement of lymph nodes) Pure osteolytic lesion Unidimensional lesion for which a\n        normal measurement is available (e.g., mediastinal width on x-ray) Evaluable disease\n        defined as malignant disease evident on physical or radiographic exam but not measurable\n        by ruler or caliper, i.e.: Pelvic masses Confluent multinodular lung metastases Skin\n        metastases CNS metastases eligible if stable for at least 4 weeks following completion of\n        surgery or radiotherapy\n\n        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy: At\n        least 3 months Hematopoietic: ANC at least 1,500 Platelets at least 100,000 Hepatic:\n        Bilirubin no greater than 1.5 mg/dL AST less than 3 times normal Renal: Creatinine no\n        greater than 1.5 mg/dL Other: No contraindication to indwelling central venous catheter No\n        active infection including HIV No other medical condition that would preclude protocol\n        compliance No pregnant or nursing women Adequate contraception required of fertile\n        patients\n\n        PRIOR CONCURRENT THERAPY: Biologic therapy: Prior biological therapy allowed Chemotherapy:\n        Prior systemic chemotherapy allowed Patients with more than 1 prior regimen analyzed\n        separately At least 4 weeks since chemotherapy (6 weeks since nitrosoureas or mitomycin)\n        Endocrine therapy: Not specified Radiotherapy: Prior skin irradiation allowed At least 4\n        weeks since wide-field radiotherapy Surgery: Fully recovered from prior surgery Other:\n        Prior topical therapy allowed Prior PUVA allowed"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "12", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 1, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002635", 
            "org_study_id": "CDR0000064085", 
            "secondary_id": [
                "YALE-HIC-7862", 
                "NCI-T94-0189D"
            ]
        }, 
        "intervention": [
            {
                "intervention_name": "filgrastim", 
                "intervention_type": "Biological"
            }, 
            {
                "intervention_name": "aminocamptothecin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Lenograstim", 
                "9-amino-20-camptothecin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "stage II cutaneous T-cell non-Hodgkin lymphoma", 
            "stage III cutaneous T-cell non-Hodgkin lymphoma", 
            "stage IV cutaneous T-cell non-Hodgkin lymphoma", 
            "recurrent cutaneous T-cell non-Hodgkin lymphoma"
        ], 
        "lastchanged_date": "July 24, 2013", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/YALE-HIC-7862"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "New Haven", 
                        "country": "United States", 
                        "state": "Connecticut", 
                        "zip": "06520-8028"
                    }, 
                    "name": "Yale Comprehensive Cancer Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60611"
                    }, 
                    "name": "Robert H. Lurie Comprehensive Cancer Center, Northwestern University"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02111"
                    }, 
                    "name": "New England Medical Center Hospital"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "PHASE II TRIAL OF 9-AMINOCAMPTOTHECIN IN ADVANCED CUTANEOUS T CELL LYMPHOMA", 
        "overall_official": {
            "affiliation": "Yale University", 
            "last_name": "John R. Murren, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "April 2000", 
            "@type": "Actual"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002635"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Yale University", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Yale University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 1995", 
        "study_design": "Intervention Model: Single Group Assignment, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2001"
    }, 
    "geocoordinates": {
        "New England Medical Center Hospital": "42.358 -71.06", 
        "Robert H. Lurie Comprehensive Cancer Center, Northwestern University": "41.878 -87.63", 
        "Yale Comprehensive Cancer Center": "41.308 -72.928"
    }
}